Delving into the Latest Updates on RD13-02 with Synapse

Overview

Basic Info

Drug Type

Universal CAR-T

Synonyms

RD13 02

Target

CD7

Mechanism

CD7 modulators(T-cell antigen CD7 modulators), Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

Anemia, AplasticCD7 positive Hematologic NeoplasmsAdult Lymphoblastic Lymphoma+ [1]

Inactive Indication-

Originator Organization

Nanjing Bioheng Biotech Co., Ltd.Startup

Active Organization

Nanjing Bioheng Biotech Co., Ltd.Startup

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 Chimeric Antigen Receptor-T(CAR-T) therapy for patients with CD7-positive relapsed or refractory natural killer/T cell lymphoma, and to evaluate the pharmacokinetics of CD7 CAR-T in patients。

Start Date31 Oct 2024

Sponsor / Collaborator

Wuhan Xiehe Hospital Tower

[+1]

NCT06622694 / Not yet recruitingPhase 1IIT

A Clinical Study of Safety, Efficacy, and Pharmacokinetics of Universal CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia

This trial is exploratory research aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD13-02, a universal CD7 CAR T therapy, in subjects with relapsed/refractory severe aplastic anemia (SAA)

Start Date07 Oct 2024

Sponsor / Collaborator

Hematology Hospital of Chinese Academy of Medical Sciences

[+1]

NCT05923541 / CompletedEarly Phase 1IIT

Clinical Study on Efficacy, Safety and Cytopharmacokinetics of RD13-02 Cell Injection in the Treatment of Patients With Recurrent or Refractory CD7-positive Hematologic Malignancies

This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL, and to evaluate the pharmacokinetics of CD7 CAR-T in patients.

Start Date26 Jun 2023

Sponsor / Collaborator

Henan Cancer Hospital

[+1]

100 Clinical Results associated with RD13-02

Login to view more data

100 Translational Medicine associated with RD13-02

Login to view more data

100 Patents (Medical) associated with RD13-02

Login to view more data

100 Deals associated with RD13-02

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anemia, Aplastic	Phase 1	CN	Nanjing Bioheng Biotech Co., Ltd.Startup	07 Oct 2024
CD7 positive Hematologic Neoplasms	Phase 1	CN	Nanjing Bioheng Biotech Co., Ltd.Startup	30 Apr 2023
Adult Lymphoblastic Lymphoma	Phase 1	CN	Nanjing Bioheng Biotech Co., Ltd.Startup	09 Feb 2023
Solid tumor	Phase 1	CN	Nanjing Bioheng Biotech Co., Ltd.Startup	09 Feb 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05716113 (ASH2024) Manual	Phase 1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma \| Adult Lymphoblastic Lymphoma CD7 Positive	18	RD13-02	eeqexujdwz(mfynjoumgh) = dnqghqlevy boduntsnte (jsrbwerdkr ) View more	Positive	09 Dec 2024
NCT05716113 (EHA2024) Manual	Phase 1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma \| Adult Lymphoblastic Lymphoma CD7 Positive	12	RD13-02	sjcllhdooh(jqjrsfezur) = None pgruqolroq (wcqaxpeqdd ) View more	Positive	14 May 2024